Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200736 | 1.00 | ATM (0.62) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL1200738 | 1.00 | ATM (0.62) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL24661545 | 0.90 | SMN1; SMN2 (0.62) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL15670028 | 0.89 | SMN1; SMN2 (0.54) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL15670029 | 0.89 | SMN1; SMN2 (0.54) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL8658251 | 0.86 | ATM (0.48) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL9513414 | 0.84 | ATM (0.53) | ATMSMN1; SMN2CTSSCTSLGAA | |
| SCHEMBL11491274 | 0.84 | ATM (0.60) | ATMSMN1; SMN2CTSSCTSLLMNA | |
| SCHEMBL1461981 | 0.84 | ATM (0.60) | ATMSMN1; SMN2CTSSCTSLLMNA | |
| SCHEMBL9511334 | 0.84 | ATM (0.53) | ATMSMN1; SMN2CTSSCTSLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078410-A1 | COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | 上海美志医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2019243273-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES | UNIVERSITÉ DE STRASBOURG (FR) | 2019-12-26 | — | — | WO | disclosed |
| US-20170007610-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2017-01-12 | — | — | US | disclosed |
| US-20170007610-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2017-01-12 | — | — | US | disclosed |
| US-20170007610-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2017-01-12 | — | — | US | disclosed |
| EP-3097093-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | Cadila Healthcare Limited (IN) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015114660-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | CADILA HEALTCHARE LIMITED (IN) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015114660-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | CADILA HEALTCHARE LIMITED (IN) | 2015-08-06 | — | — | WO | disclosed |
| US-7888351-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20110034462-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2011-02-10 | — | — | US | disclosed |
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007610-A1 | NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS | OPRK1, OPRM1, OPRD1 | ATM 4103/4885SMN1; SMN2 2680/4885CTSS 1894/4885 |
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | ATM 3361/4885SMN1; SMN2 2326/4885CTSS 1300/4885 |
| US-20110034462-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | ATM 3361/4885SMN1; SMN2 2326/4885CTSS 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.